- Chinese biotechnology company, BeiGene ( NASDAQ: BGNE ) announced Wednesday an agreement to develop messenger RNA-based therapies in partnership with InnoRNA, a biotech with expertise in LNP-based delivery technology and mRNA drug discovery.
- Per the terms of the collaboration, the two companies will jointly develop multiple mRNA-LNP programs.
- BeiGene ( BGNE ) will have the exclusive global rights for the development and commercialization of the product candidates jointly discovered by the two companies.
- In return, InnoRNA will receive an upfront cash payment in addition to tiered royalties and milestone payments based on certain development, regulatory, and commercial events.
- The company will also receive a non-exclusive license to InnoRNA’s proprietary LNP Technology in exchange for an additional upfront cash payment and milestone payments to InnoRNA.
- Read: In June, Citi argued BeiGene ( BGNE ) could benefit as China eases COVID- driven travel restrictions.
For further details see:
BeiGene in pact with InnoRNA to develop messenger RNA-based therapies